A Montreal study, to which research member Dr. Moishe Liberman contributed, shows that a drug increases the chances of survival for patients with non-small cell lung cancer (NSCLC), the most common form of lung cancer.
The drug, which restores the anti-tumor immune response, is combined with chemotherapy and administered before surgery.
The results of this study were published in the prestigious New England Journal of Medicine.
John Stagg: Identification of CD73 enzyme leads to AstraZeneca drug Oleclumab
15 October 2021
Last September, at the European Society for Medical Oncology Congress, AstraZeneca Pharmaceuticals shared the preliminary results of its recent Phase […]
Cellular aging: Francis Rodier’s team elucidates a paradox
24 November 2021
The team of Francis Rodier, a research member at the Institute, shows that cellular aging, which protects against cancer, depends […]